Androgen receptor antagonist 1

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Androgen receptor antagonist 1  纯度: 99.39%

Androgen receptor antagonist 1 是一种口服有效的完整雄激素受体 (AR) 拮抗剂，IC50 为 59 nM。Androgen receptor antagonist 1 可用于合成 PROTAC AR 降解剂，1 μM 和 10 μM PROTAC AR 降解剂作用于 LNCaP 细胞，分别导致 24% 和 47% AR 蛋白降解。

Androgen receptor antagonist 1

Androgen receptor antagonist 1 Chemical Structure

CAS No. : 1338812-36-4

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥4950 In-stock
5 mg ￥4500 In-stock
10 mg ￥8000 In-stock
25 mg ￥15500 In-stock
50 mg ￥23500 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

Androgen receptor antagonist 1 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Anti-Cancer Compound Library
  • Transcription Factor Targeted Library

生物活性

Androgen receptor antagonist 1 is an orally available full androgen receptor (AR) antagonist with an IC50 of 59 nM[1]. Androgen receptor antagonist 1 (Compound 6) can be used in the synthesis of PROTAC AR degraders, which results 24% and 47 % AR protein degradation in LNCaP cells at 1 μM and 10 μM, respectively[2].

IC50 & Target

IC50: 59 nM (androgen receptor)[1]
体外研究
(In Vitro)

Androgen receptor antagonist 1 (Compound 26; 1 nM-100 μM) shows significant cell growth inhibition effects for LNCaP and LNAR cells but not DU145 cells[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line: Prostate cancer (CaP) cells (LNCAP, LNAR, and DU145)
Concentration: 1 nM, 10 nM, 100 nM, 1 μM, 10 μM, 100 μM
Incubation Time: 7 days
Result: Antiproliferative effects of in LNCAP and LNAR cells.

体内研究
(In Vivo)

Androgen receptor antagonist 1 (Compound 26; 100 mg/kg once a day for 5 weeks) demonstrates excellent in vivo tumor growth inhibition upon oral administration in a castration-resistant prostate cancer (CRPC) animal model[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male athymic nude mice with LNCaP xenograft model of CRPC[1]
Dosage: 100 mg/kg
Administration: Orally once a day for 5 weeks
Result: Demonstrated outstanding efficacy in inhibiting tumor growth. At the given doses (100 mg/kg once a day) nearly completely suppressed tumor growth (by 90 %) and the PSA levels (78%) after 5 weeks, with no detectable body weight loss for the period of time when animals were treated.

分子量

416.90

Formula

C21H25ClN4O3
CAS 号

1338812-36-4
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 100 mg/mL (239.87 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.3987 mL 11.9933 mL 23.9866 mL
5 mM 0.4797 mL 2.3987 mL 4.7973 mL
10 mM 0.2399 mL 1.1993 mL 2.3987 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (6.00 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (6.00 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Guo C, et al. Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists. J Med Chem. 2011 Nov 10;54(21):7693-704.

    [2]. Han X, et al. Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019 Jan 24;62(2):941-964.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务